or Try an Advanced Search...

    Technical Analysis for INMB - INmune Bio Inc.

    Grade Last Price % Change Price Change
    C 11.29 4.15% 0.45
    INMB closed up 4.15 percent on Friday, April 26, 2024, on 74 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: May 1
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical INMB trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.15%
    20 DMA Support Bullish 4.15%
    Wide Bands Range Expansion 4.15%
    Gapped Down Weakness 4.15%
    Crossed Above 20 DMA Bullish 6.31%
    Older End-of-Day Signals for INMB ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Resistance about 13 hours ago
    60 Minute Opening Range Breakout about 15 hours ago
    Rose Above 50 DMA about 15 hours ago
    Up 5% about 16 hours ago
    Rose Above Previous Day's High about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    INMB Chart by TradingView
    Basic chart:

    Profile

    INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Disease Solid Tumors Immune System Immunotherapy Cancer Treatment Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Residual Disease

    Is INMB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 INmune Bio rises 2%, on $4.5M direct offering
    Apr 22 INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
    Apr 22 INmune Bio: An Opportunity In The Freefall (Rating Upgrade)
    Apr 8 INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
    Apr 1 INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
    Mar 31 INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
    Mar 29 INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
    Mar 29 INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
    Mar 28 INmune Bio GAAP EPS of -$1.67 misses by $0.02, revenue of $0.15M beats by $0.01M
    Mar 28 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
    See more INMB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.74
    52 Week Low 6.5092
    Average Volume 104,513
    200-Day Moving Average 9.62
    50-Day Moving Average 11.39
    20-Day Moving Average 10.20
    10-Day Moving Average 9.78
    Average True Range 0.90
    RSI (14) 55.75
    ADX 17.22
    +DI 26.38
    -DI 16.03
    Chandelier Exit (Long, 3 ATRs) 9.50
    Chandelier Exit (Short, 3 ATRs) 10.99
    Upper Bollinger Bands 11.96
    Lower Bollinger Band 8.45
    Percent B (%b) 0.81
    BandWidth 34.36
    MACD Line -0.24
    MACD Signal Line -0.46
    MACD Histogram 0.2187
    Fundamentals Value
    Market Cap 203.46 Million
    Num Shares 18 Million
    EPS -1.52
    Price-to-Earnings (P/E) Ratio -7.43
    Price-to-Sales 971.08
    Price-to-Book 4.86
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.64
    Resistance 3 (R3) 12.64 12.18 12.42
    Resistance 2 (R2) 12.18 11.84 12.19 12.34
    Resistance 1 (R1) 11.74 11.63 11.96 11.74 12.26
    Pivot Point 11.28 11.28 11.40 11.29 11.28
    Support 1 (S1) 10.84 10.94 11.06 10.84 10.32
    Support 2 (S2) 10.38 10.73 10.39 10.24
    Support 3 (S3) 9.94 10.38 10.17
    Support 4 (S4) 9.94